About argenx (NASDAQ:ARGX)
argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome. It is also developing ARGX-111 to treat solid tumors; ARGX-109 for the treatment of rheumatoid arthritis; ARGX-112 to treat skin inflammation; ARGX-115, a cancer immunotherapy-focused product candidate; and ARGX-116 for the treatment of dyslipidemia. The company has license and collaboration agreements with AbbVie S.Á.R.L.; Bird Rock Bio, Inc.; LEO Pharma A/S; Staten Biotechnology B.V.; and Shire International GmbH. argenx SE was founded in 2008 and is based in Breda, the Netherlands.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Trailing P/E Ratio-65.86
Forward P/E Ratio-36.30
Sales & Book Value
Annual Sales$44.74 million
Price / Sales66.30
Price / CashN/A
Book Value$12.12 per share
Price / Book7.61
EPS (Most Recent Fiscal Year)N/A
Return on EquityN/A
Return on AssetsN/A
argenx (NASDAQ:ARGX) Frequently Asked Questions
What is argenx's stock symbol?
argenx trades on the NASDAQ under the ticker symbol "ARGX."
What price target have analysts set for ARGX?
5 brokerages have issued 12 month price targets for argenx's shares. Their predictions range from $87.00 to $130.00. On average, they expect argenx's stock price to reach $108.50 in the next twelve months. View Analyst Ratings for argenx.
Who are some of argenx's key competitors?
Some companies that are related to argenx include Seattle Genetics (SGEN), Neurocrine Biosciences (NBIX), bluebird bio (BLUE), Qiagen (QGEN), AveXis (AVXS), BIO-TECHNE (TECH), Spark Therapeutics (ONCE), Crispr Therapeutics (CRSP), Halozyme Therapeutics (HALO), China Biologic Products (CBPO), Aerie Pharmaceuticals (AERI), Atara Biotherapeutics (ATRA), Repligen (RGEN), Regenxbio (RGNX) and Editas Medicine (EDIT).
Who are argenx's key executives?
argenx's management team includes the folowing people:
- Mr. Tim Van Hauwermeiren MSc, EMBA, CEO & Exec. Director (Age 46)
- Mr. Eric Castaldi, Chief Financial Officer (Age 54)
- Prof. Hans de Haard Ir, Ph.D., Chief Scientific Officer (Age 58)
- Mr. Dirk Marcel Leon Beeusaert, Gen. Counsel (Age 54)
- Dr. Torsten Dreier Ph.D., Chief Devel. Officer (Age 54)
When did argenx IPO?
(ARGX) raised $65 million in an IPO on Thursday, May 18th 2017. The company issued 3,600,000 shares at $18.18 per share. Cowen and Company and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.
Has argenx been receiving favorable news coverage?
News stories about ARGX stock have been trending somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies positive and negative press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. argenx earned a daily sentiment score of 0.15 on Accern's scale. They also assigned media stories about the company an impact score of 46.46 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
Who are argenx's major shareholders?
argenx's stock is owned by many different of retail and institutional investors. Top institutional shareholders include venBio Select Advisor LLC (2.68%), Millennium Management LLC (2.59%), Franklin Resources Inc. (1.41%), Acuta Capital Partners LLC (1.26%), BB Biotech AG (1.23%) and VHCP Management II LLC (1.08%). View Institutional Ownership Trends for argenx.
Which institutional investors are selling argenx stock?
ARGX stock was sold by a variety of institutional investors in the last quarter, including VHCP Management II LLC, Artal Group S.A., DAFNA Capital Management LLC, Franklin Resources Inc., New York State Common Retirement Fund and Bamco Inc. NY. View Insider Buying and Selling for argenx.
Which institutional investors are buying argenx stock?
ARGX stock was purchased by a variety of institutional investors in the last quarter, including BB Biotech AG, Millennium Management LLC, Loomis Sayles & Co. L P, Citadel Advisors LLC, Eventide Asset Management LLC, Acuta Capital Partners LLC, Point72 Asset Management L.P. and venBio Select Advisor LLC. View Insider Buying and Selling for argenx.
How do I buy shares of argenx?
Shares of ARGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is argenx's stock price today?
One share of ARGX stock can currently be purchased for approximately $92.20.
How big of a company is argenx?
argenx has a market capitalization of $2.97 billion and generates $44.74 million in revenue each year. The company earns $-31,730,000.00 in net income (profit) each year or ($1.40) on an earnings per share basis. argenx employs 67 workers across the globe.
How can I contact argenx?
argenx's mailing address is Willemstraat 5, Breda P7, 4811 AH. The company can be reached via phone at 329-310-3400 or via email at [email protected]
MarketBeat Community Rating for argenx (ARGX)MarketBeat's community ratings are surveys of what our community members think about argenx and other stocks. Vote "Outperform" if you believe ARGX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARGX will underperform the S&P 500 over the long term. You may vote once every thirty days.